The blood-brain barrier (BBB) is crucial to the health of the brain and is often compromised in neurological disease. Moreover, because of its barrier properties, this endothelial interface restricts uptake of neurotherapeutics. Thus, a renewable source of human BBB endothelium could spur brain research and pharmaceutical development. Here we show that endothelial cells derived from human pluripotent stem cells (hPSCs) acquire BBB properties when co-differentiated with neural cells that provide relevant cues, including those involved in Wnt/b-catenin signaling. The resulting endothelial cells have many BBB attributes, including well-organized tight junctions, appropriate expression of nutrient transporters and polarized efflux transporter activity. Notably, they respond to astrocytes, acquiring substantial barrier properties as measured by transendothelial electrical resistance (1,450 ± 140 V cm 2 ), and they possess molecular permeability that correlates well with in vivo rodent blood-brain transfer coefficients.
A r t i c l e s
The BBB is composed of specialized brain microvascular endothelial cells (BMECs) that help regulate the flow of substances into and out of the brain. Complex intercellular tight junctions limit the passive diffusion of molecules into the brain and result in blood vessels exhibiting extremely high trans-endothelial electrical resistance (TEER) in vivo 1 . In addition, efflux transporters, such as p-glycoprotein, contribute to barrier properties by returning small lipophilic molecules that diffuse into BMECs back to the bloodstream. Thus, BMECs are endowed with a network of specific transport systems to shuttle essential nutrients and metabolites across the BBB. In addition, because of its substantial barrier properties, the BBB prevents uptake of most small-molecule and virtually all biologic pharmaceuticals delivered intraveneously 2 , hampering the development of drugs for neurological disease. Conversely, BBB breakdown and dysfunction is associated with various diseases, including Alzheimer's disease, stroke, multiple sclerosis and brain tumors 3 . These considerations have led researchers to develop a variety of BBB models to enable detailed mechanistic studies and drug screens in vitro.
Most in vitro BBB models have been established using brain microvessels isolated from primary animal sources such as cow, pig, rat and mouse 4 . However, given inevitable species differences 5, 6 , a robust in vitro BBB model of human origin would be of great utility for highthroughput screening to identify brain-penetrating molecules or for the study of BBB developmental, regulatory and disease pathways in humans. Human BBB models have been established by culturing primary human (BMECs isolated from autopsy tissue or, more often, from freshly resected brain specimens derived from tumor or epilepsy patients. Issues involving BMEC availability and fidelity limit widespread use of these human BBB models 7 . Another proposed route toward a human BBB model is cell immortalization 8 .
However, immortalized BMECs have poor barrier properties, including low baseline transendothelial electrical resistance (TEER) [8] [9] [10] and discontinuous tight junction protein expression 8 . We sought to create a robust, scalable human BBB model using hPSCs, including both human embryonic stem cells (hESCs) 11 and human induced pluripotent stem cells (hiPSCs) 12, 13 , which exhibit virtually unlimited self-renewal and can differentiate into somatic cell types from all three embryonic germ layers. Human endothelial cells have been generated from hPSCs by a variety of methods, including embryoid body differentiation [14] [15] [16] [17] [18] and OP9 stromal cell coculture 19, 20 . However, endothelial cells develop distinct gene and protein expression profiles that depend on microenvironmental cues during organogenesis 21 , and hPSC-derived endothelial cells with organ-specific properties have yet to be reported.
Here we describe a facile hPSC differentiation method that can reproducibly generate pure populations of endothelial cells with BBB properties. The method employs simultaneous endothelial and neural cell co-differentiation followed by purification of the BBB-like endothelial population on selective matrix. The purified endothelial cells express BBB markers, respond to astrocytic cues, and have barrier and transport properties similar to those of primary BMECs.
RESULTS

Differentiation of hPSCs into BBB endothelial cells
In vivo, BBB specification begins as endothelial cells forming the perineural vascular plexus invade an embryonic brain microenvironment comprising neuroepithelial cells, radial glia, neuroblasts and neurons. Notably, much of this early BBB induction occurs in the absence of astrocytes [22] [23] [24] [25] . The cells of the developing embryonic brain provide relevant BBB induction cues, such as Wnt7a and
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Wnt7b, that signal through the canonical Wnt-β-catenin pathway to help promote BBB specification of endothelial cells 26, 27 . We therefore hypothesized that a strategy that simultaneously differentiates hPSCs to both neural and endothelial lineages could lead to hPSC-derived endothelial cells with BBB attributes. Both neural and endothelial cells can be generated from pluripotent stem cells by directed differentiation in adherent culture [28] [29] [30] . Thus, we developed a custom two-dimensional hPSC differentiation strategy that promotes neural and endothelial co-differentiation, in essence providing a microenvironment resembling the embryonic brain in vitro. The strategy was initially implemented using the IMR90-4 hiPSC line 13 , and protocol robustness was subsequently validated with multiple hiPSC and hESC cell lines (Fig. 1a) . IMR90-4 hiPSCs were expanded on Matrigel-coated plates in defined mTeSR1 medium for 2-3 d (Fig. 1a) . To initiate neural and endothelial co-differentiation, we cultured the colonies in unconditioned medium for 3-4 d, at which time we observed many cells expressing nestin (Fig. 1b, left, green) , a marker expressed in immature neural progenitors, and βIII tubulin (Fig. 1b, left, red) , a neuronal marker. During IMR90-4 hiPSC differentiation, 86% of the entire cell population could be classified as potential neural progenitors (23% nestin + βIII tubulin − ), immature neurons (58% nestin + βIII tubulin + ) or neurons (5% nestin − βIII tubulin + ), mimicking the microenvironment of the embryonic brain (Fig. 1c) . We observed a similar distribution during H9 hESC differentiation (Supplementary Fig. 1a ). Within this large immature neural population, very small clusters of cells exhibiting endothelial morphology and PECAM-1 expression but lacking characteristic BBB tight junctions began to form (Fig. 1d, left and e) .
At day 6 of unconditioned medium treatment, substantially more IMR90-4-derived nestin − βIII tubulin + neurons were present (26%), whereas the nestin + βIII tubulin + population had decreased to 29% (Fig. 1b, right and c) . In contrast, only small clusters of cells expressing glial fibrillary acidic protein (astrocyte marker) and α-smooth muscle actin (potential pericyte-smooth muscle marker) on the order of 30-50 cells per 10 6 could be identified by immunocytochemistry (Supplementary Fig. 2) , and, given their low abundance, these cells probably do not have a major role in BBB specification. As the neural population matured at 5-7 d unconditioned medium treatment, the endothelial regions became larger and more prevalent, and BBB glucose transporter GLUT-1, tight junction proteins occludin and claudin-5, and p-glycoprotein were coexpressed in the endothelial population (Fig. 1f) . Although peripheral endothelia express one or more of these markers, the composite set of markers is quite restricted to brain endothelium 31 . In the following, we refer to endothelial cells that express tight junction proteins, p-glycoprotein and elevated amounts of GLUT-1 as hPSC-derived BMECs. 
We quantified the population of hPSC-derived BMECs by flow cytometry. For this analysis, we defined BMECs as cells having both PECAM-1 expression and elevated GLUT-1 expression as compared with the low basal GLUT-1 expression exhibited by cells during the first 4 d of differentiation (GLUT-1 + PECAM-1 + , see Online Methods for gating details). For IMR90-4-derived BMECs, this population comprised ~30% of the cultures at day 6 of unconditioned medium treatment ( Fig. 1g and Table 1) . Thus, the neural and endothelial populations combined represented ~95% of the total differentiating culture at day 6 of unconditioned medium treatment. This hPSCderived BMEC population was further expanded for 2 d in a custom endothelial cell medium that included factors known to facilitate primary BMEC growth with some selectivity (basic fibroblast growth factor (bFGF) and platelet-poor plasma derived serum 32 ), and the percentage of GLUT-1 + PECAM1 + cells in the differentiating IMR90-4 culture increased to 66% (Fig. 1d , right and g, 6 d unconditioned medium, 2 d endothelial cell medium, and Table 1 ). The BMEC differentiation process yielded on average 11.6 PECAM-1 + GLUT-1 + cells per input hPSC after 6 d in unconditioned medium and 2 d in endothelial cell medium, indicating proliferation of endothelial cell progenitors and/or endothelial cells during differentiation. At this point, all GLUT-1 + PECAM1 + cells coexpressed the requisite BBB markers (Supplementary Fig. 3 ). Moreover, in endothelial cell medium, the hPSC-derived BMECs exhibited a commensurate increase in BBB properties as indicated by substantially increased expression of GLUT-1 protein ( Table 1) . In contrast, if instead the cultures were grown for two additional days in unconditioned medium (8 d unconditioned medium) rather than in endothelial cell medium, the percentage of IMR90-4-derived BMECs increased to a lesser extent although the total PECAM-1 + population increased to similar numbers ( Fig. 1g and Table 1 ), indicating the importance of the endothelial cell medium treatment for selective BMEC expansion and conferral of BBB phenotypes on the endothelial cell population. Similar results were observed for the additional hiPSC 33 and hESC 11 lines tested (Fig. 1a) , with cell line-dependent BMEC differentiation efficiency ( Supplementary Figs. 4-6 and Table 1 ). For the H9 hESC line, extended culture (7 d for unconditioned medium and 6 d for endothelial cell medium) was required to increase BMEC yield from 16% to 35% of the population ( Fig. 1g and Table 1 ). Thus, in general, two-dimensional differentiation and expansion of hPSCs for 6-7 d in unconditioned medium followed by 2-6 d in endothelial cell medium generated substantial yields of highly enriched hPSCderived BMECs.
Wnt--catenin signaling in hPSC-derived BMEC specification
Murine in vivo and in vitro studies have demonstrated that canonical Wnt-β-catenin signaling is necessary for the onset of brain angiogenesis and the acquisition of BBB properties such as GLUT-1 (refs. 26, 27) and claudin-5 expression 34 . Canonical Wnt ligands Wnt7a and Wnt7b have been specifically implicated in BBB development in vivo and are expressed by neural progenitors 26, 27 . Therefore, we assayed for WNT7A and WNT7B expression in the neural progenitor-neuron populations and monitored the temporal nuclear localization of β-catenin in the developing hPSC-derived BMEC population. Nearly all nestin + cells and βIII tubulin + cells (that is, all three developing neural populations evaluated in Fig. 1c ) expressed WNT7A and WNT7B transcripts at day 4 of unconditioned medium treatment ( Fig. 2a and Supplementary Figs. 1b-j and 7a) . Although junctional β-catenin in PECAM-1 + endothelial cells was widespread, nuclear β-catenin was sparse at this time (7 ± 4% of PECAM-1 + endothelial cells; Fig. 2b, left) . By day 6 of unconditioned medium treatment when large percentages of the culture had adopted a BMEC phenotype, the majority of the nestin + and βIII tubulin + cells maintained expression of WNT7A, except for some bipotent βIII tubulin + cells ( Supplementary Fig. 7b-e) , whereas the WNT7B transcript was no longer detected. The percentage of PECAM-1 + endothelial cells exhibiting detectable nuclear β-catenin substantially increased to 40 ± 6% at 5 d of unconditioned medium treatment (Fig. 2b, middle) and nearly all PECAM-1 + endothelial cells (90 ± 6%) had nuclear β-catenin after 6 d unconditioned medium and 2 d endothelial cell treatment (Fig. 2a, right and Supplementary Fig. 8 for other hPSC lines). Notably, elevated expression of GLUT-1 was nearly exclusively detected in cells that also contained nuclear β-catenin (Fig. 2b , middle); this is consistent with in vivo reports of absence of BBB GLUT-1 in endothelial-specific β-catenin knockout mutants 26 and GLUT-1 downregulation in the vascular plexus of WNT7A-WNT7B double knockout mutants 27 .
As all cell lines tested exhibited nuclear β-catenin localization during BMEC differentiation, we also assessed linkage to Wnt-mediated processes by evaluating transcript expression of Wnt receptors and target genes during IMR90-4 differentiation (Fig. 2c) . We compared gene expression in later (7 d , unconditioned medium) cultures containing ~30% PECAM-1 + GLUT-1 + BMECs and early (3 d, unconditioned medium) cultures devoid of these cells. As expected, transcripts indicative of BMEC differentiation, such as ABCB1 (p-glycoprotein) and SLC2A1 (GLUT-1), were upregulated during this time period (Fig. 2c) . Wnt receptors Frizzled4 (FZD4) and Frizzled6 (FZD6) have been implicated in angiogenesis of retinal [35] [36] [37] and brain endothelial cells 26 , with the FZD6 transcript being highly expressed in adult brain endothelial cells compared with lung and liver endothelial cells 26 . 
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Transcripts of Frizzled4 and Frizzled6 were upregulated in concert with the emergence of IMR90-4-derived GLUT-1 + PECAM1 + BMECs in the differentiating cultures, whereas the FZD7 gene, which encodes Wnt receptor Frizzled7, which has no known linkage to brain endothelial differentiation 26, 27 , was downregulated during the same time frame. The gene products for β-catenin-associated transcription factor LEF1 and Wnt-downstream gene FST (encoding follistatin) were also upregulated during this time. In addition, the STRA6 gene, which encodes a BBB-resident vitamin A transporter 38 that has been identified as a Wnt target gene 39 and is enriched in adult brain endothelial cells compared with lung and liver endothelial cells 26 , was upregulated during the course of BBB differentiation. APCDD1, which is highly enriched in adult brain endothelial cells compared with lung and liver endothelial cells 26 and is an antagonist of Wnt signaling 40 , was unchanged over the time course of analysis, potentially suggesting a more prominent role of APCDD1 in adult BBB maintenance through Wnt pathway regulation rather than in BBB development. Treatment with the Wnt signaling inhibitors secreted frizzled receptor protein 2 (SFRP2) or XAV-939 led to downregulation of LEF1, FST, STRA6, FZD6, SLC2A1 and ABCB1 (Fig. 2c) , further supporting the involvement of Wnt signaling in regulating these transcripts. Moreover, differentiating IMR90-4 cultures treated with XAV-939 showed a reduction in GLUT-1 + cells from 64% to 46% (Fig. 2d and Table 1 ). Treatment with XAV-939 also led to a slight reduction in the overall percentage of PECAM-1 + cells (68% to 61%), thus giving a 19% net reduction in the overall percentage of PECAM-1 + endothelial cells that became PECAM-1 + GLUT-1 + BMECs. Notably, the presence of XAV-939 did not alter claudin-5 or occludin localization even in GLUT-1 − endothelial cells, and western blots indicated equal amounts of claudin-5 and occludin in the differentiating cultures regardless of XAV-939 treatment (data not shown). These data compare favorably with observations in endothelial-specific β-catenin knockout mouse mutants in which brain vascular malformations lacked GLUT-1 expression but still had tight junctions 26 . Thus, although certain aspects of BMEC specification seem to be influenced by the Wnt-β-catenin pathway (for example, elevated GLUT-1 expression), this pathway is probably not exclusively responsible for BMEC specification [41] [42] [43] .
Purification of hPSC-derived BMECs
Although the two-dimensional co-differentiation strategy led to many hPSC-derived BMECs as defined by expression of tight junction proteins, p-glycoprotein and elevated GLUT-1, many characteristic BBB properties, including barrier formation and transporter activity, are best evaluated in purified, confluent monolayers. Furthermore, reverse transcription PCR (RT-PCR) analysis indicated that although the IMR90-4-derived BMECs expressed the PECAM1 transcript, they did not express endothelial transcripts encoding von Willebrand factor (vWF) and VE-cadherin during the early unconditioned medium treatment phase (Fig. 3a) . During treatment with endothelial cell medium, VE-cadherin expression was detected (Fig. 3a) , consistent with sequential expression of PECAM-1 and VE-cadherin endothelial genes observed during endothelial cell differentiation from stem cells 44 . Thus, to stimulate further maturation and facilitate purification, IMR90-4-derived BMECs were subcultured from Matrigel onto plates coated with collagen-fibronectin extracellular 32 . In endothelial cell medium, the cells grew to confluence after 1-2 d, were contact inhibited, had characteristic endothelial cell morphology (Fig. 3b) and could uptake acetylated low-density lipoprotein (Fig. 3c) . About 100% of the cells in the purified cultures expressed PECAM-1 and the requisite BBB markers as determined by flow cytometry and immunocytochemistry (Fig. 3d,e) , indicating effective and facile purification using this extracellular matrix-based selective passaging method. Notably, the cells also acquired vWF and VE-cadherin expression during subculture, indicating endothelial cell maturation (Fig. 3a,e) , and vascular character of these BMECs was further confirmed by formation of tube-like structures in the presence of vascular endothelial growth factor (VEGF; Fig. 3f ). The extent of BBB maturation achieved during treatment with unconditioned medium and endothelial cell medium and before subculture onto the fibronectin-collagen matrix was critical for obtaining this pure, confluent monolayer of BMECs. For example, when IMR90-4-derived BMECs were subcultured after just 4 d of unconditioned medium treatment, cells expressing BBB markers still developed, but did not reach confluence and in many areas showed malformed and discontinuous tight junctions (Fig. 3g) . This lack of BBB differentiation was consistent with the observation that at this stage of unconditioned medium treatment, there was minimal β-catenin nuclear localization (Fig. 2b, left) , and no PECAM-1 + claudin-5 + cells were present (Fig. 1e) . We found similar purification results for DF19-9-11T-derived BMECs subcultured onto the collagen-fibronectin matrix ( Supplementary Fig. 9 and Table 1) , whereas DF-6-9-9T-derived BMECs (Supplementary Fig. 10 ) could also be purified, although they exhibited some discontinuous junctions (Supplementary Fig. 10c ). H9-derived BMECs could not be purified from the large percentage of nonbrain PECAM-1 + GLUT-1 − endothelial cells by the collagen-fibronectin protocol given the general affinity of endothelial cells for the collagen-fibronectin matrix. We therefore used the IMR90-4 and DF19-9-11T lines for in-depth BBB phenotype testing.
BBB phenotype of hiPSC-derived BMECs
In addition to BBB marker expression and a vascular phenotype, hiPSCderived BMECs should also respond to astrocytic cues, exhibit tight barrier properties and express functional transport systems. A hallmark of the BBB is the high TEER-a consequence of tight junction protein interactions between adjacent BMECs. To measure the TEER for the BMEC monolayers, we seeded IMR90-4-derived BMECs onto Transwell filters coated with collagen-fibronectin matrix and grew them to confluence in endothelial cell medium to create a standard two-compartment BBB model (Fig. 4a) . Immunofluorescent detection of ZO-1, occludin and claudin-5 showed maintenance of continuous cell-cell contacts between BMECs on the filter surface, similar to the tight junctions observed on fibronectin-collagen-coated polystyrene culture dishes (Supplementary Fig. 11 ). Initial TEER measurements taken at confluence were 150-175 Ω cm 2 , indicating a tightening endothelial monolayer (Fig. 4b, time 0 h ). TEER measurements after coculture with either primary rat astrocytes or non-neural human embryonic kidney 293 (HEK293) cells in endothelial cell medium were compared with monocultured IMR90-4-derived BMECs. After 24 h, TEER in the astrocyte cocultures (412 ± 38 Ω cm 2 ) was nearly twice that observed in both HEK cell coculture (236 ± 23 Ω cm 2 ) 
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A r t i c l e s and BMEC monoculture (222 ± 51 Ω cm 2 ) and remained elevated for up to 96 h, indicating a specific response to astrocytic cues, as we expected of BMECs (Fig. 4b and Table 2 ). When astrocyte coculture was done in medium containing 10% FBS, TEER of the IMR90-4-derived monolayer reached 696 ± 8 Ω cm 2 after 24 h, whereas TEER in the HEK cell cocultures was again substantially lower at 364 ± 53 Ω cm 2 ( Table 2) . Optimization of seeding density to generate a more uniform monolayer yielded IMR90-4-derived BMECs with a maximum TEER of 1,450 ± 140 Ω cm 2 upon astrocyte coculture ( Table 2) . DF19-9-11T-derived BMECs exhibited a maximum TEER of 777 ± 112 Ω cm 2 during astrocyte coculture ( Table 2 ). The hiPSC-derived BMEC monolayers typically showed maximum TEER between 24 h and 48 h of coculture and maintained elevated TEER levels up to 8 d (Supplementary Fig. 12 ). In terms of robustness, hiPSCs of differing passage number consistently yielded TEER in a range of 700-1,450 Ω cm 2 over the course of 30 individual experiments, with an average value of 860 ± 260 Ω cm 2 . For comparison, one of the highest documented TEER values for primary human BMECs obtained from fresh biopsy is 339 ± 107 Ω cm 2 (ref. 45 ) and the immortalized human BMEC cell line hCMEC/D3 reaches a maximum TEER of 199 ± 5 Ω cm 2 in response to hydrocortisone 9 , whereas peripheral endothelium exhibits a TEER in the 2-30 Ω cm 2 range.
To further validate the fidelity of the tight junctions formed by the IMR90-4-derived BMECs after coculture with astrocytes, we analyzed the cells by freeze-fracture electron microscopy (Fig. 4c) . Freeze-fracture showed networks of tight junction strands whose complexity mimicked that of high-resistance BBB endothelium in vivo. The tight junction particles were primarily associated with the protoplasmic fracture face (P-face), in contrast with lower-resistance in vitro BBB models that often undergo a switch of tight junction particles from the P-face to the E-face 46 .
The BBB in vivo is characterized not only by its high TEER but also by its impermeability to passive diffusion, its expression of various transport systems used for import and export of nutrients and metabolites and its ability to act as an active barrier to small hydrophobic molecules by using key efflux transporters like p-glycoprotein, breast cancer resistance protein (BCRP) and members of the multidrug resistance protein (MRP) family. Purified IMR90-4-derived BMECs Figure 4 Functional barrier properties and BBB characteristics of purified hiPSC-derived BMECs. (a) Schematic of two-compartment BBB model. hiPSC-derived BMECs were seeded onto a Transwell filter coated with collagen-fibronectin and cocultured with rat astrocytes to assay for induction of BBB properties. Apical (blood side) and basolateral (brain side) chambers are denoted with respect to transport assays. (b) hiPSC-derived BMECs responded to soluble cues from astrocytes. IMR90-4-derived BMECs were cultured alone (monoculture) or cocultured with either rat astrocytes or HEK cells for 96 h and TEER was monitored. Values are mean ± s.d. of triplicate filters. Preferential TEER response in astrocyte coculture compared with HEK coculture was observed for more than ten biological replicates. See Table 2 for TEER values from experiments with optimized medium and seeding density. (c) Freeze-fracture electron microscopy of IMR90-4-derived BMECs after coculture with rat astrocytes for 24 h. P, P-face; E, E-face. Red arrows, E-face groove largely devoid of tight junction particles; blue arrow, infrequent tight junction particle found at E-face; yellow arrows, complex network of tight junction particles associated with P-face. Correlation between IMR90-4-derived BMEC permeability coefficients (P e , x axis) and rodent in vivo transfer coefficients (K in , y axis). P e values (cm min −1 ) were calculated from flux experiments using triplicate filters as described in Online Methods. Values are mean ± s.d. for each compound measured in at least three such experiments. To accumulate these data, five individual coculture models (independently differentiated from undifferentiated hiPSCs) were assembled and three to six compounds were measured at a time. Sucrose P e values were also acquired from efflux transporter inhibition assay controls. Colchicine was the only compound with large variability across biological replicates (see Supplementary Table 1 npg cocultured with astrocytes expressed transcripts encoding a variety of receptors and transporters found at the BBB (Fig. 4d) , such as LDLR (low-density lipoprotein receptor), LRP1 (low-density lipoprotein receptor-related protein 1), INSR (insulin receptor), LEPR (leptin receptor), BCAM (lutheran glycoprotein), TFRC (transferrin receptor) and AGER (receptor for advanced glycation end products, RAGE). Transcripts were also detected for members of amino acid and peptide transporter families that are highly enriched at the BBB compared with other endothelium, including STRA6 (retinol-binding protein), SLC2A1 (GLUT-1), SLC7A5 (LAT1), SLC1A1 (EAAT3), SLC38A5 (SNAT5) and SLC16A1 (MCT1). Efflux transporter transcripts were also detected, including ABCB1 (MDR1 or p-glycoprotein),
and ABCC5 (MRP5). Notably, two assayed transcripts were not detected: PLVAP and SLCO1C1 (also known as SLC21A14). PLVAP (plasmalemma vesicle-associated protein) is initially expressed at the BBB during development and becomes downregulated with onset of barrier properties, but its expression remains in peripheral vessels throughout adulthood 24 . Thus, the absence of PLVAP in the IMR90-4-derived BMECs further indicates BBB specification and maturation. SLCO1C1 encodes Oatp14, an organic anion transporter whose transcript and protein product is highly enriched at the rodent but not human BBB 47, 48 . Taken together, the gene expression profile of receptors and transporters is highly representative of the BBB. Next, we screened radiolabeled small molecules of varying sizes, lipophilicity and efflux transporter recognition for relative permeability using the IMR90-4-derived BMEC-astrocyte coculture model ( Fig. 4e and Supplementary Table 1) . The measured permeability (P e ) values were highly correlated (R 2 = 0.98) with in vivo rodent brain uptake measured by in situ brain perfusion 49 . Notably, sucrose permeability (P e = 3.4 × 10 −5 cm min −1 ), which is often used to benchmark the passive barrier of in vitro models, was on the order of that in high-fidelity animal BBB models (10 −4 to 10 −5 cm min −1 ) 49, 50 and substantially lower than that in the hCMEC/D3 line (P e = 1.65 × 10 −3 cm min −1 ) 8 . Glucose, a small (180 Da) hydrophilic molecule that is actively imported across the BBB by the GLUT-1 transporter, showed a seven-fold higher permeation compared with sucrose (P e = 2.2 × 10 −4 cm min −1 ). Inulin, a large, hydrophilic polysaccharide polymer, showed similar permeation to sucrose (P e = 2.9 × 10 −5 cm min −1 ). Diazepam, a very lipophilic small molecule that shows high BBB penetration in vivo because it is not an efflux transporter substrate, had the highest in vitro permeation (1.1 × 10 −3 cm min −1 ). Colchicine and vincristine, which are also lipophilic small molecules but have limited brain uptake in vivo as they are substrates of p-glycoprotein and MRP family members, had lower P e values in vitro (9.2 × 10 −5 and 6.2 × 10 −5 cm min −1 , respectively). Prazosin, which is a substrate for efflux by BCRP but also thought to be imported by an organic cation transporter, showed slightly higher P e (2.9 × 10 −4 cm min −1 ) than colchicine and vincristine, consistent with its in vivo ranking. Notably, the 40-fold dynamic range of P e values (diazepam to sucrose) indicates the potential use of the hiPSC-derived BBB model as a drug screening tool, although future testing with a broader spectrum of compounds is needed to validate the predictive power of the model.
Although the relative exclusion of aforementioned lipophilic small molecules like colchicine, vincristine and prazosin suggests functionality of the relevant BBB efflux transporters described in Figures 3e  and 4d , we also assessed their functionality and polarity using selective inhibitors (full compound details are in Supplementary Table 2) . First, p-glycoprotein function in monocultured IMR90-4-derived BMECs was probed using rhodamine 123, a cell-permeable, fluorescent p-glycoprotein substrate. There was a 1.4-fold increase in cellular accumulation of rhodamine 123 (decrease in efflux) in the presence of cyclosporin A, a known p-glycoprotein inhibitor, but not with Ko143 or MK 571, inhibitors of BCRP and the MRP family, respectively, indicating the presence of functional p-glycoprotein in IMR90-4-derived BMECs (Fig. 4f, top) . When doxorubicin, a substrate for p-glycoprotein, BCRP and the MRPs, was added to monocultured IMR90-4-derived BMECs, it accumulated to a greater extent in the presence of cyclosporin A, Ko143 or MK 571, demonstrating the functional efflux activity of each class of transporter (Fig. 4f, top) . Next, we used directional transport assays with the IMR90-4-derived BMEC-astrocyte coculture model to demonstrate preferential efflux function in the brain-to-blood direction (basolateral to apical). For p-glycoprotein, transport of rhodamine 123 from the apical to basolateral chamber was 2.3-fold higher with cyclosporin A, but not with Ko143 or MK 571, because of inhibited efflux in the basolateral-toapical direction (Fig. 4f, bottom) . Conversely, transport of rhodamine 123 in the basolateral-to-apical direction slightly decreased upon treatment with cyclosporin A because p-glycoprotein extrusion of rhodamine 123 was blocked at the apical interface ( Supplementary  Fig. 13 ). Transport of doxorubicin from the apical to basolateral chamber was increased 1.3-fold, 1.3-fold and 1.2-fold by cyclosporin A, Ko143 and MK 571, respectively, indicating net functional polarization of p-glycoprotein, BCRP and MRP family efflux transporters (Fig. 4f, bottom) . Together, these data demonstrate both function and polarization of efflux transporters. Notably, the degree of polarization, as measured by increased flux in the presence of inhibitors, is consistent with that found in primary cultured in vitro rodent BBB systems 49 . Overall, the combination of BBB gene and protein expression, tight junction fidelity, correlative permeability for small molecules and polarized efflux transporter activity indicates that the hPSC-derived BMECs have considerable BBB character.
DISCUSSION
Compared with primary animal and human BMEC culture and immortalized cell lines, the approaches described here for generating hPSCderived BMECs that can form robust BBB models are relatively easy and scalable given the efficiency of endothelial differentiation (>60%) and the possibility of facile extracellular matrix-based purification. Other hPSC differentiation strategies using embryoid bodies, OP9 coculture and two-dimensional differentiation with endothelial factors have lower reported endothelial cell differentiation efficiencies (1-43%) and must be coupled with antibody-assisted purification methods to yield pure populations of endothelial cells [14] [15] [16] [17] [18] [19] [20] 29, 30 . Our differentiation process leads to a high yield of 11.6 PECAM-1 + GLUT-1 + BMECs per input hPSC after 8 d of differentiation, whereas recent publications using 
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A r t i c l e s OP9 coculture and embryoid body or directed differentiation methods have reported yields of 0.6 and 7.4 endothelial cells, respectively 15, 19 . Thus, our method is highly scalable and can generate sufficient cells for thousands of filters for drug screens. In addition, to our knowledge no previous methods for differentiating hPSCs have generated organspecific endothelial cells. In our study, BBB specification occurred in the presence of co-differentiating neural cells, which probably supplied many of the necessary cues normally provided by the embryonic brain microenvironment in vivo 24, 26, 27, 34, [41] [42] [43] .
Given that BMEC populations were obtained from both hESC and hiPSC lines derived via different reprogramming strategies, our model can be readily adopted by the research community for studies of brain development, disease mechanisms and drug delivery. The in vitro BBB specification process seems to involve Wnt-β-catenin signaling, which is consistent with in vivo mechanisms of brain development demonstrated in mice 26, 27, 34 . The model could therefore help elucidate other molecular mechanisms leading to human BBB differentiation. A better understanding of human BBB development may be clinically relevant for promoting BBB repair after stroke or for inhibiting recruitment of blood vessels by brain tumors. As hPSC-derived BMECs have good barrier characteristics with appropriate molecular exclusion and functional transport systems, this cellular platform should also be useful in drug screens to develop pharmaceuticals with desired brain permeability.
METHODS
Methods and any associated references are available in the online version of the paper.
